It was established with the aim of ensuring that regenerative medicine and cell therapy are carried out safely and to a high standard.

Director of the Cell Therapy Center
Asuka Morizane

Cell therapies such as CAR-T therapy require a specialized system for donor cell collection, preparation, transplantation, and post-transplant management. The Cell Therapy Center will work with and support each medical department to provide appropriate treatment to patients. In addition, when clinical trials and clinical research are conducted for regenerative medicine using stem cells, which has been attracting attention in recent years, the Center will support each medical department by managing cells and coordinating each department. Different cell therapies require specialized preparations, but by creating a platform for this and sharing know-how, it is believed that the effectiveness and safety of treatments can be improved.

What is cell therapy?

This is a treatment that uses cells from the patient or another person to treat cancer or restore lost function.

These include CAR-T therapy for leukemia, hematopoietic stem cell therapy, bone marrow stem cell therapy for spinal cord injuries, and stem cell therapy for intractable neurological diseases.

For more information about CAR-T treatment, please refer to Hematology website.

Cell Therapy Center

The center was established in November 2024 and is made up of a multidisciplinary team of medical doctors, Clinical Laboratory, pharmaceutical department, and Clinical Engineering.

Since the establishment of a quality management system is essential for the provision of human cell raw materials, we have created quality manuals and management procedures that comply with GMP/GCTP ordinances, mainly through our ISO15189-certified testing department.

  • GMP (Good Manufacturing Practice)
    Ministerial Ordinance on Standards for Manufacturing and Quality Control of Drugs and Quasi-drugs
  • GCTP(Good Gene, Cellular, and Tissue-Based Products Manufacturing Practice)
    Ministerial Ordinance on Standards for Manufacturing and Quality Control of Regenerative Medicine Products



1. Organization and Personnel System Development: Clarification of responsibilities, deployment of specialized personnel,
thorough staff training.



2. Documentation and Record Management: Documentation of procedures, accurate creation and storage of records,
construction of a management system.

3. Continuous improvement through the PDCA cycle: Identifying and analyzing issues and areas for improvement,
implementing and verifying improvement measures, and using standardization to prevent
recurrence.


4. Traceability: Using a system to accurately manage the chain of identity (COI) for cells collected from a patient, processed into a product, and returned to the same patient.
5. Other: Obtaining external audits and certifications, collecting the latest technology and information
Compliance with related laws, regulations and guidelines.

Through these efforts, we are able to ensure the quality of our human cell raw materials and provide safe and reliable products.

Organization chart

staff

  Full name Academic societies, professional qualifications, etc.
Director Morizane Asuka Affiliated Societies
The Japan Neurosurgical Society
Japan Neurosurgery Congress
The Japanese Society for Neuroendovascular Therapy
The Japanese Society for Regenerative Medicine
International Society for Stem Cell Research
Specialist Qualifications
Board Certified Surgeon in Neurosurgery
Cerebral Endovascular Therapy Specialist
Degree
Doctor of Medicine, Kyoto University Graduate School of Medicine
General Manager

Tadakazu Kondo Academic Societies
The Japanese Society of Internal Medicine
Japan Hematology Academic Societies
Japanese Society for Transplantation and Cellular Therapy
American Society of Hematology
Specialist Qualifications
Fellow of the Japanese Society of Internal Medicine (FJSIM)
Board Certified Member of the Japanese Society of Hematology
degree
Kyoto University Graduate School of Medicine Doctor of Medicine
Quality Control Department Manager Noboru Kometani Affiliated Academic Societies
The Japanese Society of Internal Medicine
The Japanese Society of Hematology
Japanese Society for Transplantation and Cellular Therapy
The Japan Society of Transfusion Medicine and Cell Therapy
Specialist qualification
Fellow of the Japanese Society of Internal Medicine (FJSIM)
Board Certified Member of the Japanese Society of Hematology
Head of Apheresis Department Yuya Nagai Affiliated Academic Societies
The Japanese Society of Internal Medicine
The Japanese Society of Hematology
American Society of Hematology
Specialist qualification
Fellow of the Japanese Society of Internal Medicine (FJSIM)
Board Certified Member of the Japanese Society of Hematology
degree
Doctor of Medicine, Kyoto University University Graduate School of Medicine
Head of Cell Preparation and Storage Department Nobuhiro Hiramoto Affiliated Academic Societies
The Japanese Society of Internal Medicine
The Japanese Society of Hematology
Japanese Society for Transplantation and Cellular Therapy
Japanese Society of Medical Oncology
Professional Qualifications
Board Certified Member of the Japanese Society of Internal Medicine
Board Certified Member of the Japanese Society of Hematology
Assistant Director of Apheresis Ryusuke Yamamoto Affiliated Academic Societies
The Japanese Society of Hematology
The Japanese Society of Internal Medicine
Specialist qualification
Fellow of the Japanese Society of Internal Medicine (FJSIM)
Board Certified Member of the Japanese Society of Hematology
degree
Doctor of Medicine, Kyoto University University Graduate School of Medicine

Clinical laboratory technician, clinical engineer, pharmacist

Treatment List

Insurance medical treatment
CAR therapy (Kymriah)
clinical trial
Click here for Clinical Research and Innovation

For companies and academia

Business Contents

Coordination with each medical department and division regarding the implementation of clinical trials and treatments at the hospital

  • Coordination with companies and external medical institutions, and consultation service
  • Cell preparation and storage management for cell therapy
  • Support for follow-up of intervention patients Collaboration with the Clinical Promotion Research Center

    *Our hospital does not manufacture cell preparations.

General public

Those who wish to undergo cell therapy

Our center does not provide consultations regarding individual illnesses.
Cell therapy and regenerative medicine are not applicable to all diseases.
The relative merits of these treatments compared to current general treatments vary depending on the type, symptoms, and progression of the disease. Please consult your doctor regarding your individual illness.